Vertex Pharmaceuticals Incorporated and bluebird bio would fund fertility preservation services for patients treated with their gene therapies for sickle cell disease under the Center for Medicare and Medicaid Services Innovation’s Medicaid payment demonstration if they choose to participate.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?